New research has recently been published that builds upon evidence from a previous trial investigating the potential of Sami-Sabinsa’s Curcumin C3 Reduct ingredient in oral care applications.
Canker sore (Recurrent Apthous Stomatitis, RAS) or the painful ulcers inside the mouth or at the base of the gums, and gingivitis, the common gum disease associated with gum bleeding, are among the common oral health care issues afflicting the population today, yet treatment regimens currently available leave much room for improvement.
In a recent clinical trial involving 30 canker sore patients and 29 patients with gingivitis, treatment with Curcumin C3 Reduct (two 100 mg chewable tablets/day) over a three week period showed remarkable results. At the end of the study, all canker sore patients were completely cured of their painful ulcerous lesions. The efficacy of C3 Reduct in treating common oral health care issues like gingivitis and was evaluated by several parameters including gingival index score, bleeding and inflammation. C3 Reduct treatment led to impressive abatement of pain, numbness, ulcer formation, dryness with no staining or allergic symptoms. The results are published as a peer-reviewed paper in Evidenced-Based Complementary and Alternative Medicine:
"Efficacy and Safety of Tetrahydrocurcuminoids for the treatment of Canker Sore and Gingivitis, “ authored by Dr. Muhammed Majeed, Shaheen Majeed, and Dr. Kalyanam Nagabhushanam.
A previously published independent clinical paper focused on the utility of C3 Reduct in oral leukoplakia which could ultimately progress to oral cancer in certain cases. C3 Reduct was applied as a 2% gel formulation in the affected areas inside the mouth. The researchers concluded that the topically applied gel was extremely effective in alleviating clinical symptoms. Remarkable histological improvement was seen in a subset of patients encouraging future long-term trials.
“Discovering herbal-based treatments in conditions where no satisfactory pharma therapy is readily available continues to drive our innovation,” said Dr. Muhammed Majeed, Founder and Chairman of the Sami-Sabinsa Group. “It is particularly satisfying when no side effects are seen in these trials and the treatment costs are eminently affordable.”